№ lp_2_3_70704
File format: docx
Character count: 5147
File size: 96 KB
This document outlines the pathway for administering intravenous Zoledronate (Aclasta) infusions to treat osteoporosis, specifying eligibility criteria, exclusions, and procedural steps.
Year:
Not specified
Region / City:
Hawkes Bay
Topic:
Osteoporosis Treatment
Document Type:
Medical guideline
Organization:
PHARMAC
Author:
Not specified
Target Audience:
Healthcare professionals
Effective Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / city:
UK
Topic:
Osteoporosis, fracture prevention, evidence-based resources
Document type:
Guidance
Organization / institution:
Royal Osteoporosis Society, Keele University
Author:
Not specified
Target audience:
Researchers, clinicians, patients, healthcare professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / city:
England
Topic:
Health, General Practice
Document Type:
Business Rules
Organization:
NHS England
Author:
General Practice Specification and Extraction Service (GPSES)
Target Audience:
GP system suppliers, GP practices
Period of Validity:
2023/2024/2425
Approval Date:
01/04/2023
Date of Amendments:
01/04/2024
Year:
2020
Country:
Australia
Subject:
Osteoporosis pharmacotherapy
Focus medicine:
Denosumab
Other medicines included:
Bisphosphonates, raloxifene, teriparatide, strontium ranelate, calcitriol
Type of document:
Drug utilisation analysis report
Data sources:
Pharmaceutical Benefits Scheme (PBS) data, MedicineInsight data
Committee:
Drug Utilisation Sub-Committee (DUSC)
Study design:
Retrospective cohort analysis
Population:
Patients aged 50 years and over
Study period:
January 2012 – June 2019 (PBS); January 2014 – December 2017 (MedicineInsight cohorts)
Geographic scope:
National
Health system context:
Pharmaceutical Benefits Scheme
Contextual description:
Analytical health policy report examining national prescribing patterns, initiation, discontinuation, and subsequent therapy use of denosumab and other osteoporosis medicines based on linked administrative and general practice data.
Document type:
Assessment scale table
Research field:
Genetic epidemiology
Topic:
Molecular association studies and osteoporosis
Assessment criteria:
Source of case, Source of control, Ascertainment of osteoporosis, Ascertainment of control, Matching, Genotyping examination, Specimens used for determining genotypes, Hardy-Weinberg Equilibrium, Association assessment, Total sample size
Scoring system:
Point-based evaluation scale
Maximum score components:
Up to 3 points per criterion depending on category
Population focus:
Osteoporosis cases and controls
Diagnostic reference:
WHO (World Health Organization) diagnostic standards
Statistical considerations:
Assessment of genotype–osteoporosis associations with appropriate statistics and adjustment for confounders
Genetic analysis method:
Genotyping with blinding and quality control considerations
Sample material types:
Blood cells, normal tissues, tumor tissues, exfoliated tissue cells
Sample size categories:
<200, 200–500, >500
Year:
2021
Region / City:
Not specified
Topic:
Osteoporosis Screening Installation
Document Type:
Installation Guide
Organization / Institution:
Department of Veterans Affairs, Office of Information Technology
Author:
Not specified
Target Audience:
VA staff, healthcare providers
Period of validity:
Not specified
Approval Date:
March 2021
Date of Changes:
Not specified
Topic:
Osteoporosis and bone health
Document Type:
Information sheet
Subject Area:
Health education
Medical Condition:
Osteoporosis
Related Condition:
Osteopenia
Screening Method:
DEXA scan (Dual Energy X-ray Absorptiometry)
Diagnostic Indicator:
T-score classification
Target Audience:
Healthcare staff and caregivers supporting individuals at risk of fractures
Referenced Organizations:
National Osteoporosis Foundation; U.S. Preventive Services Task Force
Referenced Guideline Year:
2018
Key Risk Factors:
Age over 50, female gender, family history, chronic diseases, certain medications
Diagnostic Criteria:
Bone density testing with T-score thresholds
Treatment Options:
Bisphosphonates, calcitonin, hormone-related medications, surgical intervention in rare cases
Care Considerations:
Safe transfers, fracture prevention, assistive lifting equipment for individuals with fragile bones
Document section:
Supplementary table S4
Subject:
ESR1 G2014A gene polymorphism and osteoporosis risk
Academic field:
Genetic epidemiology
Type of document:
Supplementary scientific table
Study design:
Meta-analysis of case–control studies
Population characteristics:
Female participants with specified menopausal status
Countries represented:
Mexico; Thailand
Geographic regions:
South America; East Asia
Ethnicity groups:
Mixed; Asian
Control source:
Population-based (PB); Hospital-based (HB)
Genetic focus:
ESR1 G2014A polymorphism
Variables reported:
Genotype distribution; allele distribution; minor allele frequency; Hardy–Weinberg equilibrium p-value
Sample information:
Cases and controls with genotype counts (A/A, A/G, G/G)
Total samples reported:
640; 228; 358; 352; 66
Authors cited:
Gómez R et al.; Ongphiphadhanakul B et al.; Wajanavisit et al.
Years of referenced studies:
2001; 2003; 2005; 2007; 2015
Year:
2026
Institution:
Queen Margaret University
Department:
Centre for Person-centred Practice Research
Project Title:
Lydia X Osteoporosis Project
Funding:
Gateway awards scheme
Project Phase:
Fourth phase
Research Focus:
Osteoporosis prevention, living with osteoporosis, healthcare practitioner knowledge and skills
Methodology:
Person-centred research, experience-based co-design study, knowledge exchange
Team Members:
Erna Haraldsdottir, Gemma Stevenson, Vicki Waga, Research Assistant (starting January 2026)
Opportunities:
Meetings attendance, data collection, data management, analysis, ethics applications, dissemination activities, knowledge exchange with staff and students
Target Audience:
Health care professionals, students, people living with osteoporosis
Start Date:
April 2026
Mentors:
Gemma Stevenson, Vicki Waga, Erna Haraldsdottir
Community Engagement:
Networking and educational meetings for patients and professionals
Year:
2026
Organization:
Canberra Health Services
Department:
Neonatology
Document Type:
Procedure
Target Audience:
Medical Officers, Registered Nurses, Midwives, Student Nurses under supervision
Scope:
Neonates from birth to 44 weeks corrected gestational age
Related Policies:
Neonatal Intensive Care Drug Manual, ANMF guidelines
Definitions Included:
Blood Glucose Levels, Hyperglycaemia, Significant Hyperglycaemia
Treatment Recommendations:
Insulin infusion, glucose monitoring, TPN and enteral feeding guidance
Risks Addressed:
Hypoglycaemia, glucose delivery variability, insulin-plastic binding
Year:
2026
Region / City:
European Union
Subject:
Pharmaceutical Product Information
Document Type:
Pharmaceutical Summary
Organization:
European Medicines Agency
Author:
European Medicines Agency
Target Audience:
Healthcare professionals
Period of validity:
Ongoing
Approval Date:
2026
Date of Modifications:
2026
Contextual Description:
The document outlines the product characteristics, indications, dosage, administration guidelines, and precautions for the pharmaceutical product Tysabri, as approved by the European Medicines Agency.
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical submission for drug listing
Document Type:
Pharmaceutical submission
Organization:
Janssen-Cilag Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
March 2025
Note:
Context
Year:
2022
Region / City:
Australia
Topic:
Medical treatment approval and submission for pembrolizumab and lenvatinib
Document type:
Submission for drug listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical professionals, health regulators
Period of validity:
2022 onward
Approval date:
August 10, 2021
Amendment date:
Not specified
Note:
Year
Topic:
Infusion Therapy Plans
Document Type:
Internal Update
Organization:
Duke Health
Target Audience:
Ambulatory Clinicians
Specialties:
Hematology, Solid Organ Transplant, Oncology, Pediatrics
Related Locations:
Duke Specialty Infusion, South Durham Infusion, Oncology Treatment Center, DUH Macon Pond Infusion, DUH Cary Infusion, DRAH Infusion Clinic
Therapy Plans:
Apheresis, Oncology/ABMT, Transplant, Peds/PBMT, Iron Products
Therapy Plan Features:
Silo-based Therapy Management, Multi-Specialty Integration
Year:
2023
Region / City:
Australia
Theme:
Oncology, Pharmaceutical
Document Type:
Submission
Organization / Institution:
Merck Sharp & Dohme (Australia) Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, policymakers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2018
Region / City:
Australia
Topic:
Pharmaceutical Submission, Cancer Treatment
Document Type:
Submission
Organization / Institution:
Takeda Pharmaceuticals Australia Pty Ltd
Author:
Takeda Pharmaceuticals Australia Pty Ltd
Target Audience:
Healthcare professionals, PBAC
Period of Validity:
Ongoing
Approval Date:
23 May 2018
Date of Amendments:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Oncology / Colorectal Cancer Treatment
Document Type:
Medical submission
Agency / Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Not specified
Target Audience:
Medical practitioners
Effective Period:
Ongoing
Approval Date:
Not provided
Date of Revision:
Not provided
Year:
2023
Region / city:
N/A
Topic:
Smart infusion pumps, medication infusion, safety
Document type:
Draft Safe Practice Statements
Organization / institution:
Institute for Safe Medication Practices (ISMP)
Author:
N/A
Target audience:
Healthcare providers, clinicians, medical staff
Period of validity:
N/A
Date of approval:
N/A
Date of modifications:
N/A
Context:
This document outlines safe practices for the implementation and use of smart infusion pumps in healthcare settings, with a focus on medication safety and infusion protocols.
Note:
Year
Topic:
Home Health Services, Durable Medical Equipment, Home Infusion Services, Authorization
Document Type:
Authorization Process Description
Organization / Institution:
CareCentrix, BlueCard
Target Audience:
Healthcare Providers, BlueCard Providers
Year:
2022
Region / City:
ACT and surrounding NSW
Topic:
Paediatric Diabetes Care, Insulin Pump Therapy
Document Type:
Clinical Guideline
Organization:
Canberra Health Services (CHS)
Author:
Canberra Health Services, Paediatric Endocrinology and Diabetes Service
Target Audience:
Paediatric Diabetes Healthcare Providers
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Year:
2026
Region / city:
Canberra
Topic:
Insulin infusion management in hospital settings
Document type:
Procedure
Organization / institution:
Canberra Health Services
Author:
Not specified
Target audience:
Medical officers, nurses, midwives, ICU/HDU/ED staff at North Canberra Hospital
Effective period:
Not specified
Approval date:
Not specified
Revision date:
Not specified